Labcorp Announces Key Appointments to Oncology Leadership Team
February 09 2021 - 11:02AM
Business Wire
Labcorp (NYSE: LH), a leading global life sciences company,
today announced the appointments of Prasanth Reddy, MD, MPH, and
Robert Phillips, PhD, to its oncology team, advancing Labcorp’s
leadership position and capabilities in cancer diagnosis,
treatment, and drug development.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210209005900/en/
Photo (Courtesy of Labcorp): Prasanth
Reddy, MD, PhD
Dr. Reddy will serve as senior vice president and enterprise
oncology head of the company’s enterprise oncology unit, and Dr.
Phillips will be vice president and head of enterprise oncology
science. The enterprise oncology unit will utilize the combined
assets of the drug development and diagnostics businesses,
leveraging biomarkers and companion diagnostics to help bring the
right treatment to the right patient at the right time.
“I am thrilled to welcome Dr. Reddy and Dr. Phillips to our
oncology leadership team,” said Dr. Paul Kirchgraber, CEO, Labcorp
Drug Development. “We are proud to be a leader in advancing science
and innovation in cancer diagnosis and discovering new therapies to
serve pharmaceutical companies, oncologists, researchers, and
patients. We will continue to expand our capabilities in oncology,
and we are excited to build a world-class leadership team in this
area.”
Dr. Reddy was most recently vice president of medical affairs at
Foundation Medicine, Inc. (FMI). He is triple board-certified in
internal medicine, medical oncology, and hematology, and he
practiced medicine and served in leadership positions for more than
10 years in various clinical settings including academia, private
practice, and managed care. Prior to FMI, Dr. Reddy worked as a
national leader developing oncology service line treatment pathways
at the Adventist Health System. Dr. Reddy earned a bachelor’s
degree in microbiology and psychology from Kansas State University,
and he earned his medical degree from the University of Kansas
Medical Center, where he also completed his internal medicine
residency and clinical hematology and oncology fellowship. Dr.
Reddy obtained a master’s degree in public health through a
National Institutes of Health Clinical Research Curriculum Award
(K30) and is an alumnus of Harvard Business School. Additionally,
he is a fellow of the American College of Physicians and is a
Certified Physician Executive.
Dr. Phillips is a scientist with many years of experience in
biomarkers, patient selection, and development of drug-linked
diagnostics, with a focus on oncology. He joins Labcorp from
Daiichi-Sankyo, where he was vice president and head of
translational science, and where he oversaw companion diagnostics
efforts. Dr. Phillips also served as vice president and head of
precision medicine at Pfizer, and prior to that, at Regeneron
Pharmaceuticals, he was head of precision medicine for all
therapeutic areas and he co-founded the Regeneron Genetics Center.
He previously worked as the deputy head for the oncology biomarkers
and imaging group for Novartis Oncology and spent nine years at
Merck, where he led the basic research molecular profiling group
and Merck’s oncology biomarkers efforts. He received his doctorate
in cell biology from the University of Michigan in Ann Arbor and
completed his post-doctoral training in molecular biology at
Princeton University.
About Labcorp
Labcorp is a leading global life sciences company that provides
vital information to help doctors, hospitals, pharmaceutical
companies, researchers, and patients make clear and confident
decisions. Through our unparalleled diagnostics and drug
development capabilities, we provide insights and accelerate
innovations to improve health and save lives. With over 70,000
employees, we serve clients in more than 100 countries. Labcorp
(NYSE: LH) reported revenue of $11.5 billion in FY2019. Learn about
Covance by Labcorp at www.Covance.com, and Labcorp at
www.Labcorp.com, or follow us on LinkedIn and Twitter @Labcorp.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking statements,
including but not limited to statements with respect to the
Company’s future operations, expansion of offerings and
capabilities, and opportunities for future growth. Each of the
forward-looking statements is subject to change based on various
important factors, many of which are beyond the Company’s control,
including without limitation, the impact of the COVID-19 pandemic
on our business and financial condition, as well as on general
economic, business, and market conditions, competitive actions and
other unforeseen changes and general uncertainties in the
marketplace, changes in government regulations, including
healthcare reform, customer purchasing decisions, including changes
in payer regulations or policies, other adverse actions of
governmental and third-party payers, changes in testing guidelines
or recommendations, the effect of public opinion on the Company’s
reputation, adverse results in material litigation matters, failure
to maintain or develop customer relationships, our ability to
develop or acquire new products and adapt to technological changes,
failure in information technology, systems or data security, and
employee relations. These factors, in some cases, have affected and
in the future (together with other factors) could affect the
Company’s ability to implement the Company’s business strategy and
actual results could differ materially from those suggested by
these forward-looking statements. As a result, readers are
cautioned not to place undue reliance on any of our forward-looking
statements. The Company has no obligation to provide any updates to
these forward-looking statements even if its expectations change.
All forward-looking statements are expressly qualified in their
entirety by this cautionary statement. Further information on
potential factors, risks and uncertainties that could affect
operating and financial results is included in the Company’s most
recent Annual Report on Form 10-K and subsequent Forms 10-Q,
including in each case under the heading RISK FACTORS, and in the
Company’s other filings with the SEC.
# # #
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210209005900/en/
Labcorp Media:
Christopher Allman-Bradshaw — 336-436-8263 Media@Labcorp.com Investors: Clarissa Willett —
336-436-5076 Investor@Labcorp.com
Labcorp (NYSE:LH)
Historical Stock Chart
From Sep 2024 to Oct 2024
Labcorp (NYSE:LH)
Historical Stock Chart
From Oct 2023 to Oct 2024